Repligen Corp. (RGEN)
165.18
+0.50
(+0.30%)
USD |
NASDAQ |
Sep 11, 16:00
165.00
-0.18
(-0.11%)
After-Hours: 20:00
Repligen Enterprise Value : 9.201B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 9.201B |
| September 10, 2026 | 9.173B |
| September 09, 2026 | 9.194B |
| September 08, 2026 | 9.390B |
| September 04, 2026 | 9.338B |
| September 03, 2026 | 9.451B |
| September 02, 2026 | 9.639B |
| September 01, 2026 | 9.474B |
| August 31, 2026 | 10.09B |
| August 28, 2026 | 9.827B |
| August 27, 2026 | 10.15B |
| August 26, 2026 | 10.05B |
| August 25, 2026 | 10.13B |
| August 24, 2026 | 10.13B |
| August 21, 2026 | 10.10B |
| August 20, 2026 | 10.05B |
| August 19, 2026 | 9.832B |
| August 18, 2026 | 9.256B |
| August 17, 2026 | 9.419B |
| August 14, 2026 | 9.294B |
| August 13, 2026 | 9.331B |
| August 12, 2026 | 9.230B |
| August 11, 2026 | 9.178B |
| August 10, 2026 | 9.088B |
| August 07, 2026 | 9.129B |
| Date | Value |
|---|---|
| August 06, 2026 | 8.877B |
| August 05, 2026 | 8.829B |
| August 04, 2026 | 8.332B |
| August 03, 2026 | 8.179B |
| July 31, 2026 | 7.837B |
| July 30, 2026 | 7.983B |
| July 29, 2026 | 7.850B |
| July 28, 2026 | 8.082B |
| July 27, 2026 | 7.276B |
| July 24, 2026 | 7.327B |
| July 23, 2026 | 7.645B |
| July 22, 2026 | 7.785B |
| July 21, 2026 | 7.610B |
| July 20, 2026 | 8.090B |
| July 17, 2026 | 8.189B |
| July 16, 2026 | 8.263B |
| July 15, 2026 | 8.235B |
| July 14, 2026 | 8.183B |
| July 13, 2026 | 8.056B |
| July 10, 2026 | 8.020B |
| July 09, 2026 | 8.003B |
| July 08, 2026 | 7.634B |
| July 07, 2026 | 7.771B |
| July 06, 2026 | 7.863B |
| July 02, 2026 | 7.916B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioLife Solutions, Inc. | 1.642B |
| Anika Therapeutics, Inc. | 266.01M |
| Danaher Corp. | 164.20B |
| Liquidia Corp. | 5.845B |
| Harmony Biosciences Holdings, Inc. | 1.966B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 5.008M |
| Revenue (Quarterly) | 204.13M |
| Total Expenses (Quarterly) | 199.12M |
| EPS Diluted (Quarterly) | 0.0884 |
| Gross Profit Margin (Quarterly) | 49.25% |
| Profit Margin (Quarterly) | 2.45% |
| Earnings Yield | 0.44% |
| Operating Earnings Yield | 0.76% |
| Normalized Earnings Yield | 0.4941 |